“Eva’s broad experience and deep knowledge in later-stage clinical development will be a valuable addition to our team, strengthening our capabilities for ongoing and future projects,” says Patric Stenberg, CEO at Gesynta Pharma. “I look forward to collaborating with her to bring better treatments to patients.”

Eva Johnsson

Eva Johnsson joins from Grünenthal, where she served as Senior Global Program Lead in the pain and inflammation therapeutic area. Prior to that, she had a long career at AstraZeneca R&D, holding several senior roles with global clinical responsibility. She is associate professor at the University of Gothenburg.

“Joining Gesynta Pharma as CMO and VP Clinical Development is an exciting new chapter for me. I am eager to work with this talented team, focusing on patient benefits and driving innovation. With a passion for science, I look forward to advancing our pipeline and delivering transformative treatment alternatives for patients suffering from endometriosis, inflammation, and pain,” says Eva Johnsson.

As Eva Johnsson is appointed, Charlotte Edenius, the company’s VP Clinical R&D, will shift to a comprehensive strategic role as VP R&D Strategy.